Influence of MYBL2 on Drug Resistance in Ovarian Cancer and It's Underlying Mechanism Based on Bioinformatics Analysis

OBJECTIVE To analyze the association of MYBL2 with drug resistance in ovarian cancer. METHODS Used GEPIA online tool to detect the mRNA expression of MYBL2 in normal ovary tissue and ovarian cancer. Used GEO profiles database to analyze the mRNA expression of MYBL2 in cisplatin sensitive and cisplatin resistant A2780 cell lines. Km-plot was used to perform OS survival rate. Comprehensive bioinformatic analyses were performed through gene interaction analysis, genetic pathway enrichment analysis, text mining and miRNA-mRNA interaction analysis to further prove MYBL2 regulated ovarian cancer drug resistance and its underlying mechanism. RESULTS The expression of MYBL2 was higher in ovarian cancer compared with normal ovary. The expression of MYBL2 was higher in cisplatin resistant A2780 compared with cisplatin resistant A2780. Most proteins closely interacted with MYBL2 were associated with drug resistance in ovarian cancer. Using genetic pathway enrichment to analyze genes interacted with MYBL2, found the most enriched pathway was cell cycle. Text mining showed besides cell cycle, gene expression, cell proliferation, apoptotic process were also significantly associated with MYBL2, ovarian cancer and drug resistance. miRNA-mRNA interaction analysis found that all 12 miRNAs targeted to MYBL2 are associated with ovarian cancer drug resistance or tumorigenesis. CONCLUSION MYBL2 is associated with ovarian cancer drug resistance, and possibly by regulating cell cycle.